693 related articles for article (PubMed ID: 30597611)
1. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
Martinez BK; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL
Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
Adv Ther; 2021 Jul; 38(7):3771-3788. PubMed ID: 34031859
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
Curr Med Res Opin; 2020 Jul; 36(7):1081-1088. PubMed ID: 32347755
[No Abstract] [Full Text] [Related]
10. Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy.
Alberts MJ; He J; Kharat A; Ashton V
Am J Cardiovasc Drugs; 2022 Jul; 22(4):425-436. PubMed ID: 35092000
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
Coleman CI; Thompson S; Ashton V; Palladino M; Bunz TJ
J Natl Med Assoc; 2020 Aug; 112(4):395-401. PubMed ID: 32493618
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
Coleman CI; Antz M; Bowrin K; Evers T; Simard EP; Bonnemeier H; Cappato R
Curr Med Res Opin; 2016 Dec; 32(12):2047-2053. PubMed ID: 27633045
[TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Lip GYH; Keshishian AV; Kang AL; Dhamane AD; Luo X; Li X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Di Fusco M; Garcia Reeves AB; Yuce H; Deitelzweig S
J Intern Med; 2021 Jan; 289(1):42-52. PubMed ID: 32602228
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
[TBL] [Abstract][Full Text] [Related]
15. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis.
Coleman CI; Bunz TJ; Eriksson D; Meinecke AK; Sood NA
Diabet Med; 2018 Aug; 35(8):1105-1110. PubMed ID: 29663521
[TBL] [Abstract][Full Text] [Related]
17. Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study.
Fu EL; Desai RJ; Paik JM; Kim DH; Zhang Y; Mastrorilli JM; Cervone A; Lin KJ
Am J Kidney Dis; 2024 Mar; 83(3):293-305.e1. PubMed ID: 37839687
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
[TBL] [Abstract][Full Text] [Related]
19. Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
Milentijevic D; Lin JH; Connolly N; Chen YW; Kogan E; Shrivastava S; Sjoeland E; Alberts MJ
J Stroke Cerebrovasc Dis; 2021 May; 30(5):105715. PubMed ID: 33743312
[TBL] [Abstract][Full Text] [Related]
20. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
